16 applications cleared under PLI scheme for drug intermediates and APIs
New Delhi: Ministry of Chemicals and Fertilizers has recently accorded approvals to 16 applicants under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.
The setting up of these 16 plants will lead to total committed investment of Rs.348.70 crore and employment generation of about 3,042 by the companies. The commercial production of these plants is projected to commence from 1st April, 2023 onward.
The applications of following companies, which have committed minimum/more than the minimum proposed annual production capacities and fulfill the prescribed criteria, have been approved, as under (under Target Segment IV):
S.No. | Name of Eligible Product | Name of the Applicants | Committed production capacity (in MT) | Committed Investment (Rs. in crore) |
1 | Valsartan | Honour Lab Limited | 300 | 26.88 |
2 | Losartan | Anasia Lab Private Limited | 400 | 29.12 |
3 |
Levofloxacin | Hetero Drugs Limited | 230 | 9.00 |
4 | Chemex Global | 115 | 20.00 | |
5 | Surya Life Sciences Limited | 230 | 20.00 | |
6 | Sulfadiazine | Andhra Organics Limited | 360 | 38.70 |
7 | Ciprofloxacin | Sreepathi Pharmaceuticals Limited | 900 | 16.05 |
8 |
Ofloxacin | Sreepathi Pharmaceuticals Limited | 300 | 16.05 |
9 | Global Pharma Healthcare Private Limited | 200 | 16.49 | |
10 | Telmisartan | Andhra Organics Limited | 360 | 40.00 |
11 |
Diclofenac Sodium | Kreative Actives Private Limited | 350 | 20.74 |
12 | Amoli Organics Private Limited | 175 | 6.56 | |
13 | Vapi Care Pharma Private Limited | 525 | 21.00 | |
14 | Levetiracetam | Honour Lab Limited | 840 | 31.36 |
15 | Carbidopa | Hetero Drugs Limited | 16 | 18.00 |
16 | Levodopa | Hetero Drugs Limited | 40 | 18.75 |
Read also: Govt nod to 33 API applications with over Rs 5k crore committed investment under PLI scheme
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.